PCVX Vaxcyte, Inc. Stock Quote

PCVX [NASD]

Index	-	P/E	-	EPS (ttm)	-3.10	Insider Own	1.40%	Shs Outstand	51.12M	Perf Week	-9.25%
Market Cap	959.63M	Forward P/E	-	EPS next Y	-2.15	Insider Trans	-56.40%	Shs Float	41.85M	Perf Month	-31.25%
Income	-89.20M	PEG	-	EPS next Q	-0.48	Inst Own	89.20%	Short Float	11.42%	Perf Quarter	-32.16%
Sales	-	P/S	-	EPS this Y	-190.60%	Inst Trans	4.30%	Short Ratio	11.22	Perf Half Y	-64.83%
Book/sh	6.77	P/B	2.58	EPS next Y	0.00%	ROA	-25.90%	Target Price	-	Perf Year	-
Cash/sh	7.03	P/C	2.48	EPS next 5Y	11.80%	ROE	-37.20%	52W Range	17.41 - 58.47	Perf YTD	-34.25%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-70.12%	Beta	-
Dividend %	-	Quick Ratio	8.30	Sales past 5Y	-	Gross Margin	-	52W Low	0.34%	ATR	1.66
Employees	58	Current Ratio	8.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	33.44	Volatility	7.87% 7.77%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	61.00%	Profit Margin	-	Rel Volume	0.49	Prev Close	17.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 29 AMC	Payout	-	Avg Volume	425.90K	Price	17.47
Recom	1.60	SMA20	-16.83%	SMA50	-26.47%	SMA200	-47.65%	Volume	208,832	Change	-0.68%

Jul-07-20

Initiated

Needham

Buy

$40

Jul-07-20

Initiated

Cantor Fitzgerald

Overweight

$55

Jul-07-20

Initiated

BofA Securities

Buy

$37

Apr-05-21 04:30PM	Vaxcyte to Present at 20th Annual Needham Virtual Healthcare Conference GlobeNewswire +6.26%
Mar-29-21 04:10PM	Vaxcyte Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
02:30PM	Vaxcyte Inc to Host Earnings Call ACCESSWIRE
Mar-25-21 07:11AM	UPDATE 3-Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim Reuters +11.40%
06:48AM	Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim Reuters
Mar-22-21 04:05PM	Vaxcyte to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021 GlobeNewswire -6.69%
Mar-15-21 06:34AM	We Think Vaxcyte (NASDAQ:PCVX) Can Easily Afford To Drive Business Growth Simply Wall St.
Jan-06-21 08:15AM	Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections GlobeNewswire +6.58%
Dec-22-20 08:00AM	Vaxcyte Promotes Andrew Guggenhime to President and Chief Financial Officer GlobeNewswire
Dec-10-20 06:34PM	Is PCVX A Good Stock To Buy Now? Insider Monkey
Nov-24-20 04:05PM	Vaxcyte to Present at Evercore ISI 3rd Annual HealthCONx Conference GlobeNewswire
Nov-12-20 04:15PM	Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Nov-10-20 04:41PM	Vaxcyte to Present at Jefferies Virtual London Healthcare Conference GlobeNewswire
Sep-23-20 07:00AM	Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare Companies GlobeNewswire
Sep-14-20 02:27PM	We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow Simply Wall St.
Sep-09-20 05:28PM	Vaxcyte to Present at 2020 Cantor Virtual Global Healthcare Conference GlobeNewswire
Aug-14-20 03:01PM	Dow Jones Edges Higher In New Bid For 28,000; Tesla, AMAT Stock Lead Nasdaq Investor's Business Daily +8.71%
Aug-12-20 04:59PM	CORRECTION Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire +8.00%
04:10PM	Vaxcyte Reports Second Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
Jun-16-20 04:05PM	Vaxcyte Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +15.36%
Jun-12-20 11:24AM	Vaccine maker Vaxcyte's shares soar 22% in trading debut MarketWatch
06:18AM	Vaccine maker Vaxcyte upsizes IPO and prices at top end of range MarketWatch
01:06AM	Vaxcyte Announces Pricing of Upsized Initial Public Offering GlobeNewswire
Jun-03-20 08:30AM	Vaxcyte Appoints Halley E. Gilbert to Board of Directors GlobeNewswire
May-21-20 08:30AM	SutroVax Announces Name Change to Vaxcyte GlobeNewswire

Vaxcyte, Inc., a preclinical-stage biotechnology vaccine company, develops novel vaccines to prevent or treat infectious diseases worldwide. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting Porphyromonas gingivalis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in Foster City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairman Jeff	VP, Research	Mar 26	Option Exercise	0.04	4,750	190	6,158	Mar 29 07:18 PM
Fairman Jeff	VP, Research	Mar 26	Sale	23.88	4,750	113,433	1,408	Mar 29 07:18 PM
PICKERING GRANT	President & CEO	Mar 19	Option Exercise	1.79	15,000	26,850	593,691	Mar 23 08:49 PM
PICKERING GRANT	President & CEO	Mar 19	Sale	25.77	15,000	386,550	578,691	Mar 23 08:49 PM
Wright-Mitchell Jane	General Counsel	Mar 15	Option Exercise	2.03	2,500	5,075	4,062	Mar 17 04:55 PM
Wright-Mitchell Jane	General Counsel	Mar 15	Sale	27.30	2,500	68,239	1,562	Mar 17 04:55 PM
Sauer Paul	SVP Process Dev, Manufacturing	Mar 11	Option Exercise	1.79	2,500	4,475	80,399	Mar 15 04:29 PM
Sauer Paul	SVP Process Dev, Manufacturing	Mar 11	Sale	25.00	2,500	62,500	77,899	Mar 15 04:29 PM
Fairman Jeff	VP, Research	Feb 26	Option Exercise	0.04	4,750	190	6,158	Mar 02 05:37 PM
Fairman Jeff	VP, Research	Feb 26	Sale	23.93	4,750	113,663	1,408	Mar 02 05:37 PM
PICKERING GRANT	President & CEO	Feb 22	Option Exercise	1.79	15,000	26,850	593,691	Feb 24 04:23 PM
Wassil Jim	Chief Operating Officer	Feb 22	Option Exercise	2.42	3,000	7,260	19,381	Feb 24 04:25 PM
PICKERING GRANT	President & CEO	Feb 22	Sale	26.47	15,000	397,036	578,691	Feb 24 04:23 PM
Wassil Jim	Chief Operating Officer	Feb 22	Sale	26.77	3,000	80,299	16,381	Feb 24 04:25 PM
Wright-Mitchell Jane	General Counsel	Feb 16	Option Exercise	2.03	2,500	5,075	4,062	Feb 17 04:55 PM
Wright-Mitchell Jane	General Counsel	Feb 16	Sale	26.95	2,500	67,375	1,562	Feb 17 04:55 PM
Sauer Paul	SVP Process Dev, Manufacturing	Feb 11	Option Exercise	1.79	2,500	4,475	80,399	Feb 16 07:46 PM
Sauer Paul	SVP Process Dev, Manufacturing	Feb 11	Sale	26.65	2,500	66,624	77,899	Feb 16 07:46 PM
Hopfner Robert Lorne	Director	Feb 10	Sale	26.53	78,158	2,073,658	1,405,418	Feb 10 07:22 PM
Hopfner Robert Lorne	Director	Feb 09	Sale	28.19	220,744	6,223,692	1,483,576	Feb 10 07:22 PM
Hopfner Robert Lorne	Director	Feb 08	Sale	25.79	79,796	2,058,117	1,704,320	Feb 10 07:22 PM
Hopfner Robert Lorne	Director	Feb 03	Sale	25.06	2,768	69,366	1,784,116	Feb 04 08:51 PM
Hopfner Robert Lorne	Director	Feb 02	Sale	25.13	14,234	357,700	1,786,884	Feb 04 08:51 PM
Hopfner Robert Lorne	Director	Jan 28	Sale	25.07	2,000	50,140	1,801,118	Feb 02 12:17 PM
Hopfner Robert Lorne	Director	Jan 27	Sale	25.30	2,140	54,142	1,803,118	Jan 27 06:02 PM
Fairman Jeff	VP, Research	Jan 26	Option Exercise	0.04	4,750	190	6,158	Jan 28 04:36 PM
Fairman Jeff	VP, Research	Jan 26	Sale	25.27	4,750	120,014	1,408	Jan 28 04:36 PM
Hopfner Robert Lorne	Director	Jan 26	Sale	25.30	18,142	458,958	1,805,258	Jan 27 06:02 PM
Hopfner Robert Lorne	Director	Jan 25	Sale	25.81	34,972	902,745	1,823,400	Jan 27 06:02 PM
Hopfner Robert Lorne	Director	Jan 22	Sale	25.16	11,383	286,396	1,858,372	Jan 22 06:10 PM
Hopfner Robert Lorne	Director	Jan 21	Sale	25.11	100	2,511	1,869,755	Jan 22 06:10 PM
Wassil Jim	Chief Operating Officer	Jan 20	Option Exercise	2.42	3,000	7,260	19,381	Jan 21 07:12 PM
Hopfner Robert Lorne	Director	Jan 20	Sale	25.35	19,046	482,816	1,869,855	Jan 22 06:10 PM
Wassil Jim	Chief Operating Officer	Jan 20	Sale	25.50	3,000	76,500	16,381	Jan 21 07:12 PM
PICKERING GRANT	President & CEO	Jan 19	Option Exercise	1.79	15,000	26,850	593,691	Jan 21 06:58 PM
PICKERING GRANT	President & CEO	Jan 19	Sale	25.10	15,000	376,498	578,691	Jan 21 06:58 PM
Hopfner Robert Lorne	Director	Jan 19	Sale	25.62	49,516	1,268,634	1,888,901	Jan 19 09:07 PM
Wright-Mitchell Jane	General Counsel	Jan 15	Option Exercise	2.03	2,500	5,075	4,062	Jan 19 06:29 PM
Wright-Mitchell Jane	General Counsel	Jan 15	Sale	26.00	2,500	65,000	1,562	Jan 19 06:29 PM
Hopfner Robert Lorne	Director	Jan 15	Sale	25.78	26,677	687,846	1,938,417	Jan 19 09:07 PM
Hopfner Robert Lorne	Director	Jan 14	Sale	25.88	14,918	386,078	1,965,094	Jan 19 09:07 PM
Hopfner Robert Lorne	Director	Jan 13	Sale	25.95	29,110	755,313	1,980,012	Jan 13 08:39 PM
Hopfner Robert Lorne	Director	Jan 12	Sale	26.38	18,567	489,871	2,009,122	Jan 13 08:39 PM
Sauer Paul	SVP Process Dev, Manufacturing	Jan 11	Option Exercise	1.79	2,500	4,475	80,399	Jan 12 09:43 PM
Hopfner Robert Lorne	Director	Jan 11	Sale	26.45	49,666	1,313,764	2,027,689	Jan 13 08:39 PM
Sauer Paul	SVP Process Dev, Manufacturing	Jan 11	Sale	26.21	2,500	65,527	77,899	Jan 12 09:43 PM
Hopfner Robert Lorne	Director	Jan 08	Sale	26.58	40,612	1,079,549	2,077,355	Jan 08 05:17 PM
Hopfner Robert Lorne	Director	Jan 07	Sale	28.27	47,580	1,344,887	2,117,967	Jan 08 05:17 PM
Hopfner Robert Lorne	Director	Jan 06	Sale	29.53	57,420	1,695,841	2,165,547	Jan 08 05:17 PM
Fairman Jeff	VP, Research	Dec 29	Option Exercise	1.79	740	1,325	1,408	Dec 30 08:26 PM
PICKERING GRANT	President & CEO	Dec 28	Option Exercise	1.79	5,500	9,845	578,691	Dec 29 06:01 PM
PICKERING GRANT	President & CEO	Dec 21	Option Exercise	1.79	15,000	26,850	588,191	Dec 22 08:44 PM
PICKERING GRANT	President & CEO	Dec 21	Sale	28.88	15,000	433,141	573,191	Dec 22 08:44 PM
TPG Group Holdings (SBS) Advis	Former 10% Owner	Dec 15	Sale	32.50	81,979	2,664,691	5,074,574	Dec 17 07:13 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Oct 08	Sale	50.69	167,661	8,498,065	5,001,593	Oct 09 04:22 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Oct 07	Sale	50.95	98,597	5,023,527	5,169,254	Oct 09 04:22 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Sep 30	Sale	50.27	124,656	6,265,871	5,283,818	Oct 01 05:25 PM
RA CAPITAL MANAGEMENT, L.P.	10% Owner	Sep 29	Sale	52.08	80,707	4,202,987	5,408,474	Oct 01 05:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience